Autism Spectrum Disorder Research Studies
The CADB Medicine Research Program is recruiting for two studies that examine the effects of a potential new treatment for the core symptoms of ASD.
Participant Sign Up
Participants, Click Here
Caregiver Sign Up
Caregivers, Click Here
White Plains, NY
Autism Spectrum Diagnosis
Have a Caregiver Who Can Participate
Fast Facts
Compensation Provided
About the Studies If you or a loved one has been diagnosed with Autism Spectrum Disorder (ASD), you may qualify to participate in one of two studies at Columbia University. The first study will examine the effects of a medication called Pimavanserin on behavioral rigidity and restrictive repetitive behavior in individuals with ASD. Besides taking the medication, study procedures include safety and efficacy evaluations with blood sample collections in addition to neurological/physical assessments. Participants will also receive multiple assessments that will allow the study team to provide a report of their areas of strength and difficulties. These may be helpful to their caregivers, teachers, or therapists. The second study, the Y202 study, will investigate a medication called L1-79 to treat deficits in social communication and integration in adolescents and young adults with ASD. Participants will be randomized to either receive the medication, then a placebo, or the other way around. This study will also include a number of assessments to test development, behavior, social communication skills, and ASD symptom severity. Help advance research on treating symptoms of ASD. Join a study! |
Participants, Click Here
Caregivers, Click Here
Additional Information
You or your loved one could be eligible to participate in a study if you meet the following criteria.
Eligibility Criteria:
Eligibility Criteria:
- 12-40 years old
- Diagnosed with Autism Spectrum Disorder
- Speak and understand English
- Have a parent, primary caregiver, or other adult who spends significant time with the participant
- Able to swallow study medication with liquid
- No history of a severe or unstable psychiatric condition
- No substance abuse disorders in the past 6 months
- No severe medical conditions in the past 3 months
- Not pregnant, nursing, or planning to become pregnant during the study
Pimavanserin study:
- Participants will first come to the clinic for a screening visit, where researchers will determine if they can take part in the study.
- Once a participant is in the study, they will take either pimavanserin or placebo (a dummy drug) for the first two visits. After the second visit they will take pimavanserin daily for six weeks.
- At each visit, the researchers will ask the participant how they are feeling, and they will be examined by the doctor. The participant and their caregiver may also be asked to provide some information and complete some tests to see if the medicine is having any effect.
Procedures involved in this study include physical exams, neurological exams, vital signs, blood draws, urine samples, electroencephalogram (EEG), electrocardiogram (ECG), assessments, and questionnaires.
Y202 study:
Participation includes a total of 10 in-person study visits and 4 phone calls.
- 1 in-person screening visit
- 8 in-person visits during treatment
- 4 phone call visits
- 1 in-person follow up
Participants will receive $50-75 per completed visit. Some reimbursement for travel expenses may also be available.
There is no cost for you or your loved one to participate.